spacer
The Healthcare Sales & Marketing Network celebrates 23 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Healthcare News Roundup: Biopharmaceuticals

 HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Sep 2021
FDA Approves LEXETTE (R) for Adolescent Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 20 Sep 2021
Mirati Therapeutics Appoints David Meek as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Sep 2021
Pfizer Expands Voluntary Nationwide Recall to include Four Additional Lots of CHANTIX(R) (varenicline) Tablets Due to N- Nitroso Varenicline Content
Biopharmaceuticals FDA Product Recall
 HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Sep 2021
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2021
Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2021
Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension
Biopharmaceuticals
 HSMN NewsFeed - 14 Sep 2021
Jupiter Orphan Therapeutics, Inc. Announces New Corporate Name, Jupiter Neurosciences, Inc.
Biopharmaceuticals Neurology
 HSMN NewsFeed - 13 Sep 2021
AbbVie and REGENXBIO Announce Eye Care Collaboration
Biopharmaceuticals Regenerative Medicine Ophthalmology
 HSMN NewsFeed - 9 Sep 2021
Obsidian Therapeutics Announces Closing of $115 Million Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 8 Sep 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Sep 2021
Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Sep 2021
EnteroBiotix Raises over $21m in Series A Financing to Advance its Microbiome Drug Pipeline
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 6 Sep 2021
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2021
XNK Therapeutics appoints Markus Thor as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Sep 2021
Chemomab Therapeutics Announces Appointment of Dale Pfost as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Sep 2021
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Aug 2021
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Aug 2021
Laronde Attracts $440M in First External Financing to Further Advance Endless RNA(TM) Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 27 Aug 2021
European Commission Approves BioMarin's VOXZOGO(R) (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Aug 2021
INOVIO Receives Authorization to Conduct Phase 3 Efficacy Trial of its COVID-19 DNA Vaccine Candidate, INO-4800
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 24 Aug 2021
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 23 Aug 2021
Elixiron Immunotherapeutics Announces Closing of $27 Million Series A-1 Financing Round to Progress Alzheimer's Disease and Vitiligo Clinical-Stage Assets
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Aug 2021
Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Aug 2021
Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2021
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals
 HSMN NewsFeed - 11 Aug 2021
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-184 in the Treatment of Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Aug 2021
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Aug 2021
LQT Therapeutics Announces Closing of US$19M Series A Financing to Advance Lead Compound Through Phase 1 while Advancing Portfolio Assets
Biopharmaceuticals Cardiology Venture Capital
 HSMN NewsFeed - 9 Aug 2021
SKYRIZI(R) (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Product Launch
 HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Aug 2021
FDA Approves New Treatment for Pompe Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Aug 2021
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Aug 2021
Breckenridge Announces Final Approval of its ANDA for Apixaban Tablets (generic for Eliquis(R))
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 5 Aug 2021
Aardvark Therapeutics, Inc., Completes $29m Series B Funding Led By Sorrento Therapeutics And Including Existing Investors And The Foundation For Prader-Willi Research
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Aug 2021
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2021
KalGene Pharmaceuticals Inc. an Alzheimer's focused company using a next generation engineered drug candidate, has appointed new leadership
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 3 Aug 2021
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
Biopharmaceuticals
 HSMN NewsFeed - 3 Aug 2021
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Aug 2021
Armata Pharmaceuticals Announces Chief Executive Officer Transition
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA
Older Biopharmaceuticals stories   Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.